Artículo
Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease
Figueroa, Juan Manuel; Lombardo, Mónica Edith; Dogliotti, Ariel; Flynn, Luis Pedro; Giugliano, Robert; Simonelli, Guido; Valentini, Ricardo; Ramos, Agñel; Romano, Pablo; Marcote, Marcelo; Michelini, Alicia; Salvado, Alejandro; Sykora, Emilio; Kniz, Cecilia; Kobelinsky, Marcelo; Salzberg, David Manuel; Jerusalinsky, Diana Alicia
; Uchitel, Osvaldo Daniel
Fecha de publicación:
01/10/2021
Editorial:
Dove Press
Revista:
International Journal of General Medicine
e-ISSN:
1178-7074
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Background: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture. Research Question: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? Study Design and Methods: This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322). Results: A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics. The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 [1.0%]) and those receiving placebo (10 of 198 [5.0%]). Relative risk reduction: 79.8% (95% CI 5.3 to 95.4; p=0.03). Absolute risk reduction: 4% (95% CI 0.6 to 7.4). Interpretation: In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease. Clinical Trials Registration: NCT04521322.
Palabras clave:
COVID-19
,
HOSPITAL WORKERS
,
NASAL
,
PROPHYLAXIS
,
SPRAY
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IBCN)
Articulos de INST.DE BIOLO.CEL.Y NEURCS."PROF.E.DE ROBERTIS"
Articulos de INST.DE BIOLO.CEL.Y NEURCS."PROF.E.DE ROBERTIS"
Citación
Figueroa, Juan Manuel; Lombardo, Mónica Edith; Dogliotti, Ariel; Flynn, Luis Pedro; Giugliano, Robert; et al.; Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease; Dove Press; International Journal of General Medicine; 14; 1-10-2021; 6277-6286
Compartir
Altmétricas